title: Attacks on publicly funded trials: what happens when industry does not want to know the answer.
authors.forename: Deborah
authors.initials: D
authors.lastname: Cohen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use*; D000068258:Bevacizumab; D002986:Clinical Trials as Topic / Q000191:economics; D057186:Comparative Effectiveness Research / Q000191:economics; D017277:Drug Approval / Q000191:economics*; D004345:Drug Industry / Q000191:economics*; D005380:Financing, Government; D006801:Humans; D012109:Research Support as Topic; D013222:State Medicine / Q000191:economics; D006113:United Kingdom; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000191:economics
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab